Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $14.6 million.

  • Ocular Therapeutix's Other Operating Expenses rose 2055.51% to $14.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $60.5 million, marking a year-over-year increase of 2812.61%. This contributed to the annual value of $60.5 million for FY2025, which is 2812.61% up from last year.
  • Ocular Therapeutix's Other Operating Expenses amounted to $14.6 million in Q4 2025, which was up 2055.51% from $14.9 million recorded in Q3 2025.
  • In the past 5 years, Ocular Therapeutix's Other Operating Expenses registered a high of $15.7 million during Q2 2025, and its lowest value of $9.0 million during Q1 2021.
  • In the last 5 years, Ocular Therapeutix's Other Operating Expenses had a median value of $11.5 million in 2024 and averaged $11.9 million.
  • Per our database at Business Quant, Ocular Therapeutix's Other Operating Expenses skyrocketed by 5618.36% in 2021 and then plummeted by 790.89% in 2023.
  • Ocular Therapeutix's Other Operating Expenses (Quarter) stood at $10.2 million in 2021, then grew by 12.69% to $11.5 million in 2022, then fell by 7.91% to $10.6 million in 2023, then rose by 13.54% to $12.1 million in 2024, then grew by 20.56% to $14.6 million in 2025.
  • Its Other Operating Expenses stands at $14.6 million for Q4 2025, versus $14.9 million for Q3 2025 and $15.7 million for Q2 2025.